Shin, Sarah S.
LaForge, Kate
Stack, Erin
Pope, Justine
Leichtling, Gillian
Larsen, Jessica E.
Leahy, Judith M.
Seaman, Andrew
Hoover, Daniel
Chisholm, Laura
Blazes, Christopher
Baker, Robin
Byers, Mikaela
Branson, Katie
Korthuis, P. Todd
Funding for this research was provided by:
Centers for Disease Control and Prevention (1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00, 1 NU17CE925018-01-00)
Substance Abuse and Mental Health Services Administration (H79TI081716, H79TI081716, H79TI081716, H79TI081716, H79TI081716, H79TI081716, H79TI081716)
National Institutes of Health (UH3DA044831, UH3DA044831, UH3DA044831, UH3DA044831, UH3DA044831, UH3DA044831, UH3DA044831, UH3DA044831)
National Institute on Drug Abuse (UG1DA01581, UG1DA01581, UG1DA01581, UG1DA01581, UG1DA01581)
Article History
Received: 24 March 2022
Accepted: 1 July 2022
First Online: 11 July 2022
Declarations
:
: The study was approved by the Oregon Health and Sciences University Institutional Review Board and granted a Federal Certificate of Confidentiality. All participants provided verbal consent at the time of the interview.
: Not applicable.
: Andrew Seaman has received investigator-initiated research support from Gilead and Merck Pharmaceuticals.